Private Companies 20

AUSTR

January 19, 2018: Bio-Link: Up-and-Coming Chinese Biotech BeiGene Gets $750M Worth of Love From U.S. Investors

NEWS BITES - PRIVATE COMPANIES

CAMBRIDGE, Mass. and BEIJING, China, Jan. 17, 2018 (GLOBE NEWSWIRE) -- BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of its follow-on public offering of 7,425,750 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS. The gross proceeds to BeiGene from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $750 million. In addition, BeiGene has granted the underwriters a 30-day option to purchase up to an additional 495,050 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 22, 2018, subject to customary closing conditions.

BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities.

Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, and Leerink Partners are acting as joint book-running managers. William Blair & Company, L.L.C. is acting as the co-manager.

The securities described above are being offered pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on January 16, 2018. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may be obtained for free from the offices of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling 1-631-274-2806; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 800-808-7525, ext. 6132 or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

INDEX

SECTION 1 BIO-LINK PROFILE

SECTION 2 OTHER NEWS: 2018

SECTION 3 PRESS RELEASES: 2017

SECTION 4 BIO-LINK TOP MANAGEMENT

SECTION 1 BIO-LINK PROFILE

1.1 ACTIVITIES

Bio-Link is a strategic consulting and biotechnology business development company that works with Australian and international life sciences companies and academic institutions to facilitate deals based on strategic technology analysis and consulting, business development, project management and deal negotiation. Bio-Link also provides technology scouting and representation services for Australian and international companies. Bio-Link has offices in Melbourne and Sydney.

1.2 SUMMARY

Website: http://bio-link.com/

Industry: Heathcare

SECTION 2 OTHER NEWS: 2018

January 19: Bio-Link: Up-and-Coming Chinese Biotech BeiGene Gets $750M Worth of Love From U.S. Investors

CAMBRIDGE, Mass. and BEIJING, China, Jan. 17, 2018 (GLOBE NEWSWIRE) -- BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of its follow-on public offering of 7,425,750 American Depositary Shares (ADSs), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS. The gross proceeds to BeiGene from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $750 million. In addition, BeiGene has granted the underwriters a 30-day option to purchase up to an additional 495,050 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 22, 2018, subject to customary closing conditions.

BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities.

Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, and Leerink Partners are acting as joint book-running managers.

January 19: Bio-Link: New York's Tyme Jumps as Pancreatic Cancer Drug Shines in Early-Stage Study

SAN FRANCISCO, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Tyme (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced efficacy and safety data for SM-88 in patients with advanced metastatic or recurrent pancreatic cancer. The data were presented today in a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, Calif.

"We are encouraged by the early efficacy signals demonstrated by SM-88 without report of drug-related serious adverse events in pancreatic cancer, a devastating disease that lacks safe and effective treatment options," said Giuseppe Del Priore, M.D., Chief Medical Officer of Tyme. "We look forward to exploring SM-88 in a larger prospective Phase II trial this year in pancreatic cancer patients who have failed prior therapy."

Data from 10 pancreatic cancer patients treated with SM-88 in Tyme's First Human Study or compassionate use program were evaluated for overall survival, overall response rate, progression-free survival, Eastern Cooperative Oncology Group (ECOG) performance status and pain scores.

Many evaluable patients demonstrated prolonged survival with 40 percent (4/10) surviving more than 12 months, and 30 percent (3/10) achieving a complete or partial response.

SECTION 3 PRESS RELEASES: 2017

September 18: Bio-Link: Abbott (ABT) Announces Extension Of Cash Tender Offer For All Outstanding Shares Of Series B Convertible Perpetual Preferred Stock Of Alere (ALR)

Abbott (NYSE: ABT) announced today that it is extending its previously announced tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock (the "Preferred Stock") of Alere Inc. ("Alere") at a price of $402.00 per share of Preferred Stock, plus accrued but unpaid dividends to, but not including, the settlement date of the tender offer, net to the seller thereof in cash, without interest thereon and subject to any withholding of taxes required by applicable law (the "Offer"). The Offer is being made pursuant to an Offer to Purchase, dated July 17, 2017 (the "Offer to Purchase"), and in connection with Abbott's previously announced agreement to acquire Alere (the "Merger"). The Merger is not conditioned upon, or otherwise subject to, the completion of the Offer.

The Offer is being extended to allow additional time for the consummation of the Merger, which is a condition to the completion of the Offer. The Offer was previously scheduled to expire at 11:59 p.m., New York City time, on Friday, Sept. 15, 2017 and will now expire at 11:59 p.m., New York City time, on Friday, Sept. 29, 2017 (such date and time, as it may be extended or earlier terminated, the "Expiration Date"). If, at the Expiration Date, any of the conditions to the Offer have not been satisfied or waived, Abbott may elect to further extend the Offer for any length of time and in its sole discretion, but is under no obligation to do so.

American Stock Transfer & Trust Company, LLC, the depositary for the Offer, has advised Abbott that, as of 11:59 p.m., New York City time, on Friday, Sept. 15, 2017, greater than 90% of the issued and outstanding shares of Preferred Stock had been tendered in the Offer. Holders of Preferred Stock who have already tendered their shares do not have to re-tender their shares or take any other action as a result of the extension of the expiration of the Offer.

For more information, contact Barclays Capital Inc., the Dealer-Manager for the Offer, or D.F.

August 24: Bio-Link: Ablynx Announces 2017 Half Year Results And Year-To-Date Business Update

GHENT, Belgium, 24 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced its financial results for the six-month period ending 30 June 2017, which have been prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the European Union, a business update for the year-to-date and the outlook for the remainder of the year.

Business highlights for the year-to-date

Caplacizumab - wholly-owned first-in-class anti-vWF Nanobody(Registered) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA)

completed recruitment of 145 patients in the Phase III HERCULES study, with topline results expected in late Q3 2017 received Fast Track designation for aTTP from the U.S. Food and Drug Administration (FDA)

ALX-0171 - wholly-owned inhaled anti-RSV Nanobody completed the sequential dose escalation part of the Phase IIb RESPIRE study in 36 infants hospitalised as a result of a respiratory syncytial virus (RSV) infection and subsequently initiated the parallel dose part, with topline results expected in H2 2018

Vobarilizumab - anti-IL-6R Nanobody held "end-of-Phase II" meetings with regulators in Europe and the USA to discuss the Phase IIb data in rheumatoid arthritis (RA) and the design of a potential Phase III programme

advanced the Phase II study in patients with systemic lupus erythematosus (SLE), with enrollment completed and topline results expected in H1 2018

after discussions with AbbVie and other potential pharmaceutical partners, decided to await the results of the SLE study, and the outcome of AbbVie's opt-in decision, before deciding on the future strategy for vobarilizumab Partnerships

entered into a strategic research collaboration with Sanofi on up to eight new programmes, focused initially on immune-mediated inflammatory diseases, with EUR23 million in upfront payments and up to EUR2.4 billion in potential milestones plus tiered royalties

reported encouraging results with the bi-specific anti-IL17-A/F Nanobody in a Phase Ib study in plaque psoriasis run by our partner Merck KGaA

received a EUR15 million milestone payment from Merck KGaA for the completion of a pre-clinical package for a novel Nanobody (ALX-1141) targeting ADAMTS-5 in osteoarthritis, with Merck KGaA planning to initiate a Phase I study in H2 2017

received a EUR2.5 million milestone payment from Merck & Co., Inc.

August 18: Bio-Link: Rosalind Franklin University Researcher Awarded $2 Million From NIH To Study Role Of Hormone Oxytocin In Stress, Fear and Anxiety

Rosalind Franklin University of Medicine and Science researcher Joanna Dabrowska has been awarded a five-year, $2 million grant from the National Institute of Mental Health (NIMH) to investigate the role of the hormone oxytocin in stress-induced psychiatric disorders. Her findings could lead to urgently needed new drug therapies for generalized anxiety and post-traumatic stress disorders.

The bed nucleus of the stria terminalis (BNST) plays an important role in the regulation of defensive behaviors like fear and anxiety. The image, taken from a female rat brain, reveals a variety of neuronal populations intermingling in the oval nucleus of the of the BNST, including neurons expressing tyrosine phosphatase STEP (blue) and protein kinase C delta (pink). These neurons also express oxytocin receptors, but their function is not well understood. Credit: RFU/Rachyl Shanker

Dabrowska, principal investigator for the study, and co-investigator Jeremy Amiel Rosenkranz, both faculty in the Department of Cellular and Molecular Pharmacology, will study "Modulation of the BNST activity by oxytocin role in stress, fear and anxiety." Because BNST, the bed nucleus of the stria terminalis, a limbic structure in the forebrain, is key to the translation of stress into sustained anxiety, factors that regulate its activity have untapped potential as novel therapeutic targets.

Oxytocin, which regulates a variety of social behaviors including maternal-infant and pair bonding, has garnered substantial interest as a potential pharmacotherapeutic agent for stress-induced mental disorders in humans, because it has repeatedly shown promising anti-anxiety effects observed in animal models. But despite its unique potential, the central sites and mechanisms of important oxytocin actions are poorly understood.

"Uncovering the role of oxytocin in the BNST will be a key to understanding the mechanisms underlying the neurobiology of stress-induced psychiatric disorders," Dr.

August 07: Bio-Link: New CEO Takes Over Rapamycin, Leads Funding Round With Plans for IND

Since taking over Rapamycin Holdings in July, Chief Executive Officer Dan Hargrove is moving the company forward rapidly. The company is in the process of raising $3.5 million in Series B funding and is looking to file an investigational new drug application later this year. Get Quote Name Symbol Price Change (%) BIO-BRIDGE SCIEN RG BGES 0.01 +0.00 (0.00%) SINOVAC BIOTECH RG SVA 6.68 +0.00 (0.00%) TRANSITION TTH 1.93 +0.00 (0.00%) Name Symbol Price Change (%) BIO-BRIDGE SCIEN RG BGES 0.01 +0.00 (0.00%) SINOVAC BIOTECH RG SVA 6.68 +0.00 (0.00%) TRANSITION TTH 1.93 +0.00 (0.00%)

Hargrove took over the Rapamycin after a stint as co-founder and chief development officer of Cancer Insight, Xconomy reported. With Hargrove at the helm, the company plans to initiate its first human trials for its eRapa platform, a treatments that is designed to inhibit the progression and recurrence of cancer cells. Company data has shown Rapamycin rejuvenates the immune system exhausted by age and cancer exposure and helps attack early stage bladder and prostate cancer cells, according to information on the company website. Through its mTor mechanism of action, eRapa is designed to inhibit multiplication of cancer cells within the body.

Before Rapamycin seeks approval from the U.S. Food and Drug Administration for the IND, Xconomy noted the company is waiting for additional data on "how well the drug lasts on the shelf." If Rapamycin is granted the IND, the company plans to initiate a Phase I study with 40 patients diagnosed with prostate cancer. The early study will test four doses of eRapa. Additionally, the company could initiate a Phase IIa trial later this year. Related Jobs QA Associate/Specialist - Regeneron Scientist - Flow Cytometry - Apex Life Sciences MedImmune Informatics Analyst - MedImmune Principal Biostatistician - MacroGenics Senior Scientist - AstraZeneca Sr.

August 07: Bio-Link: Supports Commitment To ALS Patient Community With Appointment Of A Vice President Of Patient Advocacy And Government Affairs

and PETACH TIKVAH, Israel, Aug. 7, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Mary Kay Turner to the position of Vice President of Patient Advocacy and Government Affairs, effective August 7, 2017. Ms. Turner joins BrainStorm from Mitsubishi Tanabe Pharma America, where she was Head of Patient Advocacy and Communications supporting the commercialization of edaravone (Radicava) for amyotrophic lateral sclerosis (ALS). Her prior industry experience includes senior sales leadership roles and she was Head of State Government Affairs and Advocacy for Bristol-Myers Squibb Company.

Logo - hi-res

"We are pleased to have Mary Kay join our company as we advance our ALS clinical program and prepare to initiate Phase 3 testing of NurOwn(Registered)," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm Cell Therapeutics. "Having a strong patient advocacy perspective and voice in the community is integral to our mission of advancing tomorrow's medicines. Mary Kay brings an extensive background in patient advocacy, government affairs and health policy. We are fortunate to have someone with her biopharma expertise and dedication to the patient community join our team."

"Mary Kay will lead the development and implementation of external collaborations that will address and support the needs of people living with ALS", said Dr. Ralph Z. Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer of BrainStorm. "Working directly with patient advocacy groups deepens our understanding of patients' needs and aligns our efforts with the broader ALS community."

"I have been impressed by the progress BrainStorm has made with NurOwn, particularly the outstanding Phase 2 clinical data which showed meaningful improvements in disease symptoms," said Mary Kay Turner.

August 07: Bio-Link: Launches New Diabetes Management Systems For Healthcare Providers And Consumers

ARKRAY USA, Inc., a leader in diabetes care products, announced today the launch of the ARK Care(Registered) Advance real-time diabetes management system and the ARK Care(Registered) Vita mobile app. Both systems are designed to help people with diabetes, and the healthcare professionals that care for them, have real-time access to blood glucose readings using an easy-to-use tool for monitoring and managing the disease.

Built on the foundation of simple logbooks and glucose tracking, ARK Care Advance translates that information into graphs and charts to easily identify, isolate and record changes within diabetes management. The ARK Care Vita app allows tracking of glucose readings, diet and exercise anywhere. The app will be available for download for both iOS and Android devices at the end of September.

Both ARK Care Advance and ARK Care Vita will be demonstrated at ARKRAY's booth at the American Association of Diabetes Educators annual meeting, which takes place today through August 7th in Indianapolis, IN.

"The launch of ARK Care Advance and ARK Care Vita represents the ARKRAY commitment to contributing to the health and well-being of people living with diabetes," said ARKRAY President Jonathan Chapman. "While many companies in the diabetes marketplace are reducing their investments in research and development, ARKRAY continues to deliver new products and services to help people with diabetes live a healthier and more active life."

Source: Company Website

August 04: Bio-Link: PerkinElmer Launches Clinical Whole Genome Sequencing Services

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the launch of PerkinElmer Genetics' clinical genomics services. Through its integrated laboratories in the U.S., India and China, PerkinElmer offers a global genomic lab testing platform that performs screening and diagnostic testing, specializing in newborn screening and high throughput next generation sequencing for rare inherited diseases.

PerkinElmer Genetics has two state-of-the-art CLIA-certified clinical laboratories based in Pittsburgh, PA and Branford, CT that process more than 500,000 samples a year. Their testing menus include newborn screening, biochemical profiling, 2nd tier molecular confirmatory testing, Sanger and NGS-based panels, and exome and genome sequencing.

Today, PerkinElmer Genetics has launched affordable whole exome sequencing (WES) and whole genome sequencing (WGS) services. These services are also offered in combination with biochemical profiling targeted for rapid WES and WGS for genetic disease diagnosis. While initially focused on our newborn and ViaCord customers, PerkinElmer Genetics has also developed a biochemical and molecular testing menu to meet the needs of other segments, such as pharmaceutical companies, and the markets it serves in China and India.

"We are pleased to extend our portfolio to include clinical WGS which expands the continuum of care from preconception to newborns. This offering will provide clinicians insights into the complex nature of rare and inherited diseases," said Dr. Madhuri Hegde, vice president and chief scientific officer for laboratory services of PerkinElmer's Diagnostics business group. "Because sequencing is not a stand-alone option, our ability to use dried blood spot samples and assimilate molecular and biochemical data from our global laboratories will improve interpretation of genomic variants."

July 20: Events Calendar: Bio-Link: Omega Protein Corporation (OME) Announces Second Quarter 2017 Earnings Release And Conference Call Dates

Omega Protein Corporation (NYSE:OME), a nutritional product company and a leading integrated provider of specialty oils and specialty protein products, will announce results for the second quarter ended June 30, 2017, on Wednesday, August 2, 2017, after market close.

Omega Protein Corporation Logo. (PRNewsFoto/Omega Protein Corporation)

The Company will host a conference call with members of the executive management team to discuss these results with additional comments and details. The conference call is scheduled to begin at 8:30 a.m. ET on Thursday, August 3, 2017. The call will be broadcast live at the Investor Relations section of Omega Protein's website at www.omegaprotein.com, and will be available for 30 days. In addition, listeners may dial (877) 407-3982 in North America, and international listeners may dial (201) 493-6780.

A telephonic playback will be available from 11:30 a.m. ET, August 3, 2017, through August 17, 2017. Participants can dial (844) 512-2921 in North America, and international listeners may dial (412) 317-6671. The password is 13666543. Source: Company Website

SECTION 4 BIO-LINK TOP MANAGEMENT

Christopher Boyer, Executive Director

Christopher specialises in the selling of biotechnology, as the culmination of his 20+ year career spanning its discovery, development and commercialisation. Most recently, as Executive Director of Bio-Link, Christopher led licensing efforts for a range of drug and diagnostic opportunities and closed several deals.

Prior to joining Bio-Link, Christopher served as Business Development Manager at Cryptome Pharmaceuticals, a peptide therapeutics developer in Melbourne. Earlier he was Manager, Corporate and Strategic Development at NewBiotics, a San Diego drug developer, where he negotiated contracts and contributed to a $20M co-development deal for cancer chemotherapeutics. Christopher also consulted to San Diego's Halozyme Therapeutics, a developer of therapeutic enzymes, preparing project valuations to support a successful $9.2M Series A financing.

Christopher draws upon deep technical insights acquired during his extensive R&D experience in small molecule drug discovery and molecular neuroscience, attained at Novartis and the Howard Hughes Medical Institute respectively. He earned a BS in Animal Physiology and Neuroscience from the University of California, San Diego, and augmented his business skills with an MBA in Marketing from the University of San Diego.

Christian Toouli, Executive Director

Christian is a motivated and resourceful Commercialisation Executive, dedicated to identifying, developing and generating value from biotechnology intellectual property.

As Co-Founder and Executive Director of Bio-Link Australia, Christian has worked with many of the company's Australian and international drug discovery and development clients. Accessing a large network of contacts from throughout the global biopharmaceutical industry, and with broad business development, project management and scientific expertise, he has facilitated numerous technology evaluation, IP licensing and partnering deals with international life sciences and biopharmaceutical companies.

Previously, Christian was a Postdoctoral Fellow in the Discovery Research Department of Schering-Plough Biopharma/DNAX Research Institute, the biotechnology arm of Schering-Plough Corporation. In this capacity, he investigated novel targets for oncology therapeutics and undertook competitive intelligence analyses for senior management.

During this time, Christian also served as the United States National and San Francisco Regional Life Sciences Co-Chair for Advance, the Australian expatriate professional network in the United States. Christian received his PhD from the University of Sydney for his research into cellular immortalisation and telomere maintenance at the Children's Medical Research Institute. He was awarded a Certificate in Biotechnology Management with Honours from the University of California, Santa Cruz Extension, and First-Class Honours in Biotechnology from Flinders University of South Australia. Christian is also a graduate of the Australian Institute of Company Directors.

Created by www.buysellsignals.com for News Bites Finance